Keratoconus, often referred to as ‘KCN’, is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge and optical irregularity of the cornea. This causes ‘static’ in your vision and can result in significant visual impairment.
Cross-linking is a minimally invasive outpatient procedure that combines the use of UVA light and riboflavin eye drops to add stiffness to corneas with KCN. Cross-linking creates new corneal collagen cross-links which results in shortening and thickening of collagen fibrils.
Before cross-linking After cross-linking
Boghossian Vision is proud to offer patients in our practice the first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus. This approval offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.